KAMAS Health 2.0 Presentation

36,793 views

Published on

Kinect Abnormal Motion Assessment Score presentation from Health 2.0. See http://motionassessment.com for more.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
36,793
On SlideShare
0
From Embeds
0
Number of Embeds
33,116
Actions
Shares
0
Downloads
21
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

KAMAS Health 2.0 Presentation

  1. 1. March 21, 2011<br />Copyright 2011: Team Triangle<br />Kinect Abnormal Movement Assessment System (KAMAS)<br />Team TriangleClaus C Becker, MSc, PhD, MBA Greg Borenstein, MPS (candidate) Johnny Hujol, MSCS Daniel Karlin, MD, MA Greg Kust, MPH, MBA<br />
  2. 2. March 21, 2011<br />Copyright 2011: Team Triangle<br />Executive Summary<br />Conceived and developed in 8 hours at Boston Code-a-Thon <br />Symptomatic diseases with excess of movement<br />Microsoft Kinect-based application to automate assessment <br />Home-grown and integrated open-source code<br />Multiple stakeholder perspectives (clinicians, payers, patients)<br />Framework for future development<br />
  3. 3. March 21, 2011<br />Copyright 2011: Team Triangle<br />Overview of Movement Disorders<br />Focused on hyperkinetic movement disorders<br />Dyskinesias, Choreas, Akathesias<br />Neurological conditions affecting speed, fluency, and ease of movement; and the ability to stop movement<br />KAMAS matches & complements existing clinical practices for the diagnosis & assessment of movement disorders<br />
  4. 4. March 21, 2011<br />Chorea van Sydenham<br />http://www.youtube.com/watch?v=RsIQFeYOkAg<br />
  5. 5. March 21, 2011<br />Copyright 2011: Team Triangle<br />Prevalence and Severity <br />
  6. 6. March 21, 2011<br />Copyright 2011: Team Triangle<br />Problem in Current Practice<br />Inadequate assessment of movement disorders (AIMS test)<br />Standardization<br />Frequency<br />Inter-rater reliability poor, masking progression <br />Disease progression, on a more granular & temporal basis<br />Current assessment every 3-6 months, at best<br />Gaps between assessments allow development of severe disease <br />Response to therapy (e.g. efficacy, dosing, adverse events)<br />Adherence to therapy<br />Remote monitoring<br />
  7. 7. March 21, 2011<br />Copyright 2011: Team Triangle<br />Our Approach<br />Leverage MS Kinect<br />Processing application using PrimeSense’s OpenNI middleware and OSCeleton library <br />Tracks spatial hand & knee movement <br />Calculates score based upon degree of involuntary motion<br />Clinical scorecard: Severity score compared to baseline<br />MPR* + Patient self-report + KAMAS** = Health Score <br /> *MPR: Medicine possession ratio<br />
  8. 8. March 21, 2011<br />Copyright 2011: Team Triangle<br />KAMAS Demonstration<br />
  9. 9. March 21, 2011<br />Copyright 2011: Team Triangle<br />Clinical Benefits <br />Patient<br />Less disruptive / more convenient<br />Engaged participation and self care<br />Improved care<br />Closed feedback loops<br />Earlier detection of non-response and disease progression<br />Provider<br />Clinical effectiveness & dose modification<br />Adherence measures (prescription status)<br />Time efficient<br />Reliable, quantifiable scoring<br />EMR integration (video & data)<br />At home or in clinic<br />
  10. 10. March 21, 2011<br />Copyright 2011: Team Triangle<br />Payer Benefits<br />Less $ waste (quick detection of ineffective therapy) <br />Avoid a lifetime of advanced disease costs<br />Reduce risk of expensive side effects and irreversible disease<br />Reduce hospitalizations and all cause total costs (1)<br />Clinical assessment without an office visit<br />Telemedicine compatible<br />Low cost, transparent, reproducible, auditable<br />Start-up costs not capital intensive<br />“Efforts to promote medication adherence…may lead to cost savings for managed care systems”3<br />1) Delea et al. CNS Drugs. 2011 Jan 1;25(1):53-66, 2) Wei et al. Amer J Ger Pharm. 2010 Aug;8(4):384-394, 3) Davis KL et al. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.<br />
  11. 11. March 21, 2011<br />Copyright 2011: Team Triangle<br />Issues we wrestled with<br />Short timeline (ad hoc project)<br />Kinect development environment rapidly changing<br />Investment needed to further validate and develop for clinical use <br />
  12. 12. March 21, 2011<br />Copyright 2011: Team Triangle<br />Next Steps<br />With interest from investors, refine software to include directions, progression measures, and increased range of movements<br />Data archiving and security compliance<br />Improve statistical treatment of data<br />Clinical validation possible at Tufts Medical Center<br />
  13. 13. March 21, 2011<br />Copyright 2011: Team Triangle<br />References<br />http://www.neurologychannel.com/movementdisorders/overview-of-movement-disorders.shtml<br />http://www.nlm.nih.gov/medlineplus/movementdisorders.html<br />http://www.atlantapsychiatry.com/forms/AIMS.pdf<br />http://www.webmd.com<br />Delea et al. CNS Drugs. 2011 Jan 1;25(1):53-66, <br />Wei et al. Amer J Ger Pharm. 2010 Aug;8(4):384-394<br />Davis KL et al. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.<br />Rosenheck, RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with secong-generation antipsychotics. B J Psychiatry. 2007 (191): 238-245.<br />

×